Please assess the completion status of the following clinical trial:

Trial Title: Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histologically or cytologically confirmed locally advanced breast cancer that is refractory to chemotherapy or other therapeutic agents or with a history of breast cancer with new evidence of a local recurrence (defined as a chest wall or breast recurrence and/or nodal recurrence); the diagnosis will be made based on clinical and pathologic features~* Patients must be \>18 years of age.~* Karnofsky Performance Status (KPS) score \> 70~* Patts must have normal organ function as defined below:~  * total bilirubin \< 1.5 x institutional upper limit of normal~ * AST(SGOT)/ALT(SGPT) \< 2.5 x institutional upper limit of normal~ * creatinine \< 1.5 x institutional upper limit of normal~* Patients must have left-ventricular ejection fraction \> 50% at baseline.~Exclusion Criteria:~* Patients who have contraindications to radiotherapy, such as scleroderma, dermatomyositis, or severe cutaneous manifestations of systemic lupus erythematosus (SLE)~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinib~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, or psychiatric illness/social situations that would limit compliance with study requirements~* Women who are pregnant or lactating, as well as women of child-bearing potential who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the duration of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lapatinib Plus Radiation Therapy (Type: EXPERIMENTAL): Patients receive lapatinib ditosylate PO QD on day 1 until completion of radiation therapy. Beginning on day 7, patients undergo radiation therapy for 5-7 weeks and will have their blood banked for laboratory biomarker analysis.

Based on this trial design, predict the completion outcome and termination type (if applicable).